InstalabLoading...
Physician-backed insights to optimize your health and reduce long-term risks.
Dent disease is a rare X-linked kidney disorder that begins in childhood and often progresses to chronic kidney disease. Care focuses on reducing urinary calcium loss, preventing kidney stones and nephrocalcinosis, protecting bone health, and delaying kidney failure.
Sodium polystyrene sulfonate, commonly sold as Kayexalate, has been prescribed for decades to bring down high potassium levels, especially in people with kidney disease. Yet the evidence supporting it is surprisingly thin, and the potential harms are anything but trivial. In a systematic review of gastrointestinal injury cases, roughly one in three patients with serious bowel damage from this drug died. That is not a footnote. It is the central tension of a medication still widely used in hospitals and clinics today. The core problem is a mismatch between expectation and reality. Patients and even some clinicians treat SPS as though it is a reliable, fast-acting fix for dangerous potassium levels. The research tells a different story: modest potassium reductions, an onset measured in hours to days, and a risk profile that includes bowel necrosis, heart failure, and interference with other medications you may be taking at the same time.
Sodium thiosulfate has been saving lives in emergency rooms since 1912, and it still sits on the WHO's list of essential medicines. But the most interesting story isn't the one everyone already knows. Researchers are now finding that this simple sulfur compound does far more than neutralize poisons: it scavenges damaging free radicals, protects mitochondria, tames inflammation, and behaves like a signaling molecule tied to hydrogen sulfide, one of the body's own gaseous messengers. The catch? Most of those newer roles have only been demonstrated in animal models and lab studies. What sodium thiosulfate (STS) can reliably do in humans right now, and what it might do in the future, are two very different conversations. Both are worth having.
That small, pebble-like object you just passed is not the beginning of a kidney stone problem. It is the end result of a process that has been building in your kidneys, driven by concentrated, mineral-heavy urine forming crystals over time. And here is the part most people miss: without changes, the chance of forming another stone can reach roughly 50% within five years. The stone in the toilet is worth paying attention to, but the more important story is what your urine has been doing behind the scenes and what you can do to shift the odds.
If you've ever had a urinary tract infection, you know the drill: the burning, the urgency, the constant feeling that you need to go. The first question on your mind is almost always the same. When will this be over? The short answer: with antibiotics, most uncomplicated UTIs feel significantly better within a few days and are largely resolved within a week. But the longer answer depends on whether you get treatment, how quickly you start it, and how severe your infection is. This article will walk you through what the research shows about realistic timelines, what happens if you skip or delay antibiotics, and when your symptoms should prompt a call to your doctor.
A compound made by your intestinal bacteria, not your own cells, is emerging as a surprisingly sensitive marker for severe liver disease and metabolic dysfunction. Urobilinogen, a breakdown product of the bile pigment bilirubin, shows up on routine urine dipsticks and is often ignored. But recent research ties elevated levels in the blood to early mortality in alcohol-related hepatitis and to insulin resistance, suggesting this "waste product" deserves a closer look. What makes urobilinogen especially interesting is that it sits at the intersection of your liver, your gut microbiome, your kidneys, and your metabolism. Its levels don't just reflect one organ. They reflect how well an entire system is working.
A toddler can have alkaline phosphatase levels above 1,000 U/L and be perfectly fine. Meanwhile, a persistent elevation of just 50 U/L above average in an adult with kidney disease is linked to a roughly 17% increase in death risk. Same lab marker, wildly different implications. That's the core tension with high alkaline phosphatase (ALP): it's a signal, not a diagnosis. ALP is an enzyme produced mainly by the liver and bones. An elevated reading on your blood work simply means one of those sources is churning out more than expected. What matters is which source, how long it's been elevated, and what else is going on with your health.
Only about 15% of the magnesium in a magnesium oxide tablet actually gets absorbed. The other 85 to 90% passes straight through your gut and out in your stool. That's not a manufacturing flaw. It's the very property that makes magnesium oxide work as a laxative, and it's also why a single 400 mg tablet carries relatively low risk of systemic toxicity in most people. But it raises an obvious question: if you're taking it for something other than constipation, is this really the form you want? That depends on what you're using it for, how much you're taking, and how well your kidneys work. The clinical picture is more nuanced than most supplement labels suggest.
Two genetic variants in the APOL1 gene, common in people of African ancestry, protect against parasitic infections but dramatically increase risk of chronic kidney disease (CKD). Understanding these variants highlights how genes interact with lifestyle and environment, and points toward precision strategies for prevention and treatment.
The formula your lab uses to "correct" your calcium level for low albumin gets it wrong a surprising amount of the time. In geriatric and hypoalbuminemic patients, corrected calcium can miss true hypocalcemia in 28 to 47 percent of cases. That is not a rounding error. It is a fundamental problem with a decades-old shortcut that medicine has been slow to abandon. Corrected calcium was designed to estimate biologically active calcium when albumin (a blood protein that binds calcium) is abnormally low. The idea sounds reasonable: if less protein is around to hold calcium, the raw total calcium number looks artificially low, so the formula bumps it up. But the research increasingly shows that this "bump" frequently overcorrects, making your calcium look normal when it actually is not.
Your creatinine level looks normal, so your kidneys are fine, right? Not necessarily. A growing body of research shows that a different blood marker, cystatin C, can reveal declining kidney function and elevated cardiovascular risk in people whose routine labs raise no red flags. In some populations, adding cystatin C to the picture reclassifies people from "normal" kidney function into lower categories that carry substantially higher risks of heart attack, stroke, heart failure, and death. Cystatin C is a small protein (13 kDa) produced by all nucleated cells in the body and cleared almost entirely through glomerular filtration in the kidneys. Because your serum level closely mirrors how well your kidneys are filtering, it serves as a powerful window into both kidney health and the cardiovascular trouble that often travels with it.
In a study of 1,511 kidney stone formers, those taking potassium citrate actually reported better overall quality of life and fewer complaints of nausea and stomach upset than those not taking it. That's not the profile of a supplement with a harsh side effect burden. For most people with normal kidney function, potassium citrate is well tolerated, and clinical trials consistently report that serious adverse events are rare. The concern, and it's a real one, is a specific group of people for whom potassium citrate can become genuinely dangerous.
Uric acid, the final breakdown product of purines in your body, can now be measured in blood, urine, and even saliva. That matters because it's not just a gout marker anymore. It's a biomarker tied to kidney disease, cardiovascular risk, preeclampsia, and oxidative stress. And both high and low levels can signal problems, from gout on one end to neurodegenerative disease on the other. The testing landscape has shifted fast. Standard lab tests remain the gold standard for accuracy, but a wave of newer options, including portable biosensors, paper-based strips with smartphone readouts, and saliva tests, are making it possible to monitor uric acid outside the clinic entirely.
Chronic kidney disease (CKD) has become one of the most pressing global health challenges of the 21st century. It affects an estimated 10% of the world’s population, and its burden continues to rise with increasing rates of diabetes, hypertension, obesity, and aging populations. The insidious nature of CKD lies in its silent progression. Many individuals do not realize they have kidney damage until the disease has advanced to stages where intervention options are limited. Identifying the earliest signals of renal dysfunction has therefore become a central goal of nephrology and primary care. For decades, the urinary microalbumin to creatinine ratio (ACR or MCR) has been considered the gold standard biomarker for the early detection of CKD, particularly in diabetes and hypertension. By measuring small increases in albumin excretion in relation to creatinine concentration, clinicians can detect subtle changes in glomerular permeability before full-blown proteinuria emerges. Yet despite its widespread use, growing research has questioned whether the microalbumin creatinine ratio is truly the best early marker of kidney disease or whether alternative biomarkers may be more sensitive and specific.
A urine test showing white blood cells (WBCs) does not mean you have a urinary tract infection. That is the single most important thing to understand about this result, and it runs counter to what many people assume. The medical term is pyuria, and while it often points to irritation or infection somewhere in the urinary tract, the traditional cutoff used to flag it as "abnormal" is set so low that it catches enormous numbers of people who have no infection at all. The research points to a straightforward problem: the classic threshold of 10 WBCs per microliter leads to overdiagnosis and unnecessary antibiotics, particularly in older women. Better cutoffs exist, but they vary depending on who you are.
Low blood urea nitrogen (BUN) on a lab report tends to trigger a specific kind of worry: something must be wrong, and that something must be causing problems. But the clinical research tells a surprisingly consistent story. Low BUN, by itself, is not described as causing a recognizable pattern of symptoms. The studies that have examined BUN across different patient populations focus almost entirely on the risks of high BUN. Groups with lower BUN serve as the healthy reference point, not as a population experiencing its own set of complaints. That doesn't mean a low result is meaningless. It means the number is pointing you somewhere else, toward a cause worth investigating rather than a symptom list to match against.
When we think about kidney health, most of us have heard of “creatinine” levels as the go-to test. But in recent years, doctors have been paying more attention to another blood test: the cystatin C test. Unlike creatinine, cystatin C is less affected by factors like age, sex, or muscle mass, which makes it a promising alternative for measuring kidney function. Even more interesting, studies suggest that cystatin C may also be an early warning sign for heart disease and overall mortality.
Most people who find out they have a kidney cyst want a simple answer: how big is too big? The honest answer is that no single size automatically makes a simple kidney cyst dangerous. But the research is clear that risk rises meaningfully once cysts reach about 1.5 to 2 centimeters, and it keeps climbing from there, especially when other factors pile on. That's the part most explanations skip. Size matters, but it's only one variable. How many cysts you have, how fast they're growing, where they sit in the kidney, and whether your kidney function is changing all shape whether a cyst is something to watch or something to act on.
For decades, serum creatinine has been the cornerstone of kidney function assessment, used to calculate the estimated glomerular filtration rate (eGFR). However, creatinine is influenced by age, sex, diet, and muscle mass, often leading to inaccurate estimations of renal function, especially in vulnerable populations. An alternative biomarker, cystatin C, has emerged as a promising candidate for improving the accuracy of eGFR.
A BNP of 100 pg/mL is the number most guidelines flag as clinically significant. But risk doesn't flip on like a switch at 100. In people without heart failure, BNP levels as low as 10 to 29 pg/mL have been linked to roughly 2.5 times higher mortality compared to the lowest values. That means "dangerous" is less about crossing a single line and more about where you sit on a rising slope of risk, shaped by your age, kidney function, weight, and symptoms. BNP, or B-type natriuretic peptide, is a protein your heart releases when it's under strain. The higher the level, the harder your heart is working. But the number on your lab report doesn't mean the same thing for everyone, and the context you're in (emergency room, routine checkup, ICU) changes interpretation dramatically.